LGALS9 and neoplasm: Additionally, a specific subset of tumor-infiltrating immune cells responsive to GAL-9 blockade has been identified, leveraging Authors to suggest that a combinatorial therapeutic approach able to boost the antitumor efficacy of anti-GAL-9 therapy could be applied [172].